Yang Shen

Yang Shen possesses extensive experience in antibody engineering, currently holding the position of Executive Director at Regeneron since February 2018, where prior roles included Senior Director and Director. At Eli Lilly and Company from September 2014 to January 2018, Yang served as a Senior Research Advisor and Research Advisor, leading a team in bispecific antibody engineering and overseeing various projects related to oncology biologics. Yang's background includes significant contributions at ImClone Systems, where leadership roles included Director of Antibody Engineering and Senior Scientist, focusing on antibody stability engineering and supporting candidate selections for various projects. Yang's academic credentials include a Ph.D. in Structural Biology from Columbia University and a B.S. in Biotechnology from Peking University.